-
Endpoints News1 week ago
AnaptysBio spins out biotech operations; Affibody’s data in hidradenitis suppurativa
Plus, news about Zenas and Ysios Capital: 🌀 AnaptysBio’s spinout: The independent public company, called First Tracks Biotherapeutics, is expected to start trading on April 20....
-
Endpoints News1 week ago
FDA approves Rocket’s gene therapy for ultra-rare immune disease
A rare disease gene therapy from Rocket Pharmaceuticals has garnered FDA approval after an earlier rejection for manufacturing problems. The FDA on Thursday granted accelerated approval...
-
Endpoints News1 week ago
FDA approves Novo Nordisk’s once-weekly insulin
The FDA finally greenlit Novo Nordisk’s once-weekly insulin for type 2 diabetes, making it the first US-approved longer-acting alternative to daily basal treatment for this indication....
-
Endpoints News1 week ago
AstraZeneca’s in vivo CAR-T led to early responses, but one death in China trial
New clinical trial data on the in vivo CAR-T therapy that AstraZeneca acquired last year suggest that while the experimental treatment can curb multiple myeloma in...
-
Endpoints News1 week ago
Novartis to spend up to $2B on Excellergy and its next-gen Xolair candidate
With its blockbuster drug Xolair set to face biosimilar competition, Novartis said it will pay up to $2 billion in upfront and certain milestone payments to...
-
Endpoints News1 week ago
Recursion appoints former Exelixis CMO; More executive moves at Incyte
→ Recursion has hired a new top doctor, bringing on Vicki Goodman as chief medical officer. Goodman previously served as CMO of the cancer biotechs Exelixis...
-
Endpoints News1 week ago
AstraZeneca’s COPD antibody gets Phase 3 wins in broader-than-expected population
AstraZeneca’s investigational antibody for chronic obstructive pulmonary disease has succeeded in two late-stage studies, despite having previously failed in a mid-stage trial. And, unexpectedly, the company...
